WuXi AppTec lands on Pentagon Biosecure blacklist — US biotech pivots to Indian CRAMS
11 Jun, 04:24 IST · Plays out over months · 1 source
Key facts
What the reporting establishes, before any reading of it.
- Pentagon adds WuXi AppTec to Biosecure blacklist (per FiercePharma)
- Defacto bar on US biotech contracts with WuXi for govt-funded projects
- Trillions of dollars of CRAMS + custom synthesis business reroutes
- Indian CDMO/CRAMS players (Syngene, Divi's, Laurus) prime beneficiaries
How the news spreads
Step by step — from the first companies it hits to whole sectors.
Who it hits first
- Pentagon Biosecure blacklist on WuXi AppTec — US biotech contracts pivot to India CRAMS; multi-year tailwind
Who may gain
- SYNGENE
- DIVISLAB
- LAURUSLABS
- GLENMARK
Along the supply chain
Downstream
US biotech delivery timelines stabilize; cost slightly higher than China but compliance certain
Upstream
Higher API + intermediate procurement from India over China
Where demand moves
Business
US biotech R&D contracts reroute from WuXi to Indian CDMOs; Asian capacity rationalisation
Capital
Long-only allocation into Indian CRAMS theme; ETF flows benefit
How it spreads across sectors
CRAMS
primary beneficiary
Healthcare
CRAMS sub-sector elevation
Pharma
structural positive
When it plays out
Immediate
Sector pop 2-4%
Medium term
Multi-year capacity expansion + multiple expansion
Short term
Contract pipeline visibility improves